hVIVO (HVO ) has secured more than £5 million of new early phase clinical trial contracts at its German subsidiary CRS since September, adding further visibility to group revenues into 2026.
The contracts have been signed with five clients, including two returning mid-sized German pharmaceutical customers, underlining CRS’ strong local reputation and long-standing relationships. These partnerships, given their volume and consistency, strengthen the group’s sales pipeline and order book for 2026 and beyond. The trials are due to start later this year and in the first half of 2026, with most of the revenue expected to be recognised next year.
The new studies will run at CRS’ Mannheim and Kiel sites and cover a range of therapeutic areas, including cardiometabolic disease, dermatology, infectious disease, renal impairment and cancer. hVIVO’s second subsidiary, Venn Life Sciences will support these contracts with its Biometry service, showing how the integration of CRS into the group is already delivering cross-selling benefits.
CRS has conducted more than 1,800 clinical trials and advises clients across feasibility, study design, trial management, recruitment, execution and close-out. Meanwhile, recruitment for CRS trials is being supported by the group’s enhanced Volunteer Management System, which is designed to improve efficiency in identifying and enrolling suitable participants for Phase I and Phase II studies in both healthy volunteers and patients.
hVIVO’s Chief Executive Dr Yamin 'Mo' Khan said: "Securing over £5 million in new contracts, including two mid-sized pharma clients, underscores our strong reputation and the strategic importance of CRS within the Group. These wins demonstrate the success of our integration strategy and the value we deliver through combined expertise across the hVIVO Group. CRS has seen an increased conversion rate of proposals to contracts year-to-date versus 2024 and with a robust sales pipeline and continued efficiency improvements, CRS remains on track to become earnings accretive in 2026."
View from Vox
These latest CRS wins highlight how hVIVO is building a broader early phase offering alongside its core human challenge franchise, while also deepening exposure to multiple therapeutic areas. The mix of new and returning German pharma customers, combined with higher proposal-to-contract conversion, points to growing commercial traction and better forward visibility into 2026.